However, the corresponding phase III study has not yet been published or independently investigated. The preparation is primarily intended for non-infected people with risk factors who cannot be vaccinated for health reasons or whose immune system does not respond adequately to the vaccination. It should also be used to treat mild to moderate Covid 19 diseases.
In the USA, there is already an emergency approval from the FDA for these cases, as is the case in Europe. The WHO also recommends the cocktail for the prevention of severe courses in patients with mild symptoms but with risk factors. (APA)